• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

发表于《药物经济学》的经济学评价的质量评估。头四年(1992年至1995年)。

Quality assessment of economic evaluations published in PharmacoEconomics. The first four years (1992 to 1995).

作者信息

Iskedjian M, Trakas K, Bradley C A, Addis A, Lanctôt K, Kruk D, Ilersich A L, Einarson T R

机构信息

Faculty of Pharmacy, University of Toronto, Ontario, Canada.

出版信息

Pharmacoeconomics. 1997 Dec;12(6):685-94. doi: 10.2165/00019053-199712060-00008.

DOI:10.2165/00019053-199712060-00008
PMID:10175980
Abstract

Our objective was to assess the quality of reporting of original economic research articles in PharmacoEconomics from inception to the end of 1995, in order to identify areas of strength and weakness, and analyse trends over time. Each regular issue of the journal was examined for original economic evaluations. Accepted articles were categorised by study type and by year of publication. A previously developed 13-item quality-scoring checklist was applied. The maximum possible score that an article could be assigned was 4.0. Quality scores were analysed over time and by study type. 54 articles were identified for analysis. Mean overall score (OS) ranged from a minimum of 1.80 to a maximum of 3.75, with a mean OS of 3.01 [standard deviation (SD) = 0.47]. The item with the highest mean score was the 'definition of study aim' (mean OS = 3.46, SD = 0.69). The item with the lowest score was 'ethical problems discussed and identified' (mean OS = 1.44, SD = 0.92). Only 4 items on the checklist had mean scores lower than 3.0. No significant time trend was apparent for OS (R2 = 0.002). Cost-benefit (mean OS = 3.25, SD = 0.85, n = 5), cost-effectiveness (mean OS = 3.11, SD = 0.97, n = 27), and cost-utility (mean OS = 3.29, SD = 0.93, n = 6) analyses had mean scores significantly higher than cost-analysis/cost-of-illness studies (mean OS = 2.51, SD = 1.14, n = 8). The mean OS for cost-minimisation studies was 2.74 (SD = 0.49, n = 8). Despite some weaknesses in particular aspects of economic evaluations published in PharmacoEconomics, we conclude that the journal has offered publications with acceptable overall quality and adequate methodology.

摘要

我们的目标是评估1995年全年《药物经济学》中原发性经济研究文章的报告质量,以确定其优势和薄弱环节,并分析随时间推移的趋势。对该期刊的每一期常规刊物进行原发性经济评估检查。录用的文章按研究类型和发表年份进行分类。应用了先前制定的包含13项内容的质量评分清单。一篇文章可能获得的最高分数为4.0分。对质量得分进行了时间和研究类型方面的分析。共确定了54篇文章用于分析。总体平均得分(OS)最低为1.80,最高为3.75,平均OS为3.01[标准差(SD)=0.47]。平均得分最高的项目是“研究目的的定义”(平均OS=3.46,SD=0.69)。得分最低的项目是“讨论并确定的伦理问题”(平均OS=1.44,SD=0.92)。清单上只有4个项目的平均得分低于3.0。OS没有明显的时间趋势(R2=0.002)。成本效益分析(平均OS=3.25,SD=0.85,n=5)、成本效果分析(平均OS=3.11,SD=0.97,n=27)和成本效用分析(平均OS=3.

相似文献

1
Quality assessment of economic evaluations published in PharmacoEconomics. The first four years (1992 to 1995).发表于《药物经济学》的经济学评价的质量评估。头四年(1992年至1995年)。
Pharmacoeconomics. 1997 Dec;12(6):685-94. doi: 10.2165/00019053-199712060-00008.
2
Quality assessment of published health economic analyses from South America.南美洲已发表的卫生经济分析的质量评估。
Ann Pharmacother. 2006 May;40(5):943-9. doi: 10.1345/aph.1G296. Epub 2006 May 2.
3
Quality assessment of economic evaluations in selected pharmacy, medical, and health economics journals.部分药学、医学及卫生经济学杂志中经济评估的质量评估
Ann Pharmacother. 1995 Jul-Aug;29(7-8):681-9. doi: 10.1177/106002809502907-805.
4
The state of health economic research in South Africa: a systematic review.南非健康经济研究状况:系统评价。
Pharmacoeconomics. 2012 Oct 1;30(10):925-40. doi: 10.2165/11589450-000000000-00000.
5
Quality assessment of pharmacoeconomic abstracts of original research articles in selected journals.所选期刊中原研论文的药物经济学摘要的质量评估
Ann Pharmacother. 1997 Apr;31(4):423-8. doi: 10.1177/106002809703100406.
6
PHARMACOECONOMIC STUDIES IN WORLD HEALTH ORGANIZATION EASTERN MEDITERRANEAN COUNTRIES: REPORTING COMPLETENESS.世界卫生组织东地中海国家的药物经济学研究:报告完整性。
Int J Technol Assess Health Care. 2017 Jan;33(2):215-221. doi: 10.1017/S026646231700037X. Epub 2017 Jun 5.
7
How often do sensitivity analyses for economic parameters change cost-utility analysis conclusions?
Pharmacoeconomics. 2004;22(5):293-300. doi: 10.2165/00019053-200422050-00003.
8
Evaluating quantity and quality of literature focusing on health economics and pharmacoeconomics in Gulf Cooperation Council countries.评估海湾合作委员会国家中聚焦于卫生经济学和药物经济学的文献数量与质量。
Expert Rev Pharmacoecon Outcomes Res. 2018 Aug;18(4):403-414. doi: 10.1080/14737167.2018.1479254. Epub 2018 May 30.
9
A Systematic Review on the Extent and Quality of Pharmacoeconomic Publications in Egypt.埃及药物经济学文献的范围和质量的系统评价。
Clin Drug Investig. 2019 Feb;39(2):157-168. doi: 10.1007/s40261-018-0730-5.
10
Review of Pharmacoeconomic Studies in Russian Cancer Research: An Outside View.俄罗斯癌症研究中的药物经济学研究综述:外部视角
Value Health Reg Issues. 2019 Sep;19:138-144. doi: 10.1016/j.vhri.2019.04.008. Epub 2019 Aug 28.

引用本文的文献

1
Methodological reviews of economic evaluations in health care: what do they target?医疗保健领域经济评估的方法学综述:它们的目标是什么?
Eur J Health Econ. 2014 Nov;15(8):829-40. doi: 10.1007/s10198-013-0527-7. Epub 2013 Aug 24.
2
Management and prevention of diabetic foot ulcers and infections: a health economic review.糖尿病足溃疡与感染的管理及预防:一项卫生经济学综述
Pharmacoeconomics. 2008;26(12):1019-35. doi: 10.2165/0019053-200826120-00005.
3
Methodologic quality of cost-effectiveness analyses of surgical procedures.外科手术成本效益分析的方法学质量

本文引用的文献

1
Canadian guidelines for economic evaluation of pharmaceuticals. Canadian Collaborative Workshop for Pharmacoeconomics.加拿大药品经济评估指南。加拿大药物经济学协作研讨会。
Pharmacoeconomics. 1996 Jun;9(6):535-59. doi: 10.2165/00019053-199609060-00008.
2
Costs of illness in cost-effectiveness analysis. A review of the methodology.成本效益分析中的疾病成本。方法学综述。
Pharmacoeconomics. 1994 Dec;6(6):536-52. doi: 10.2165/00019053-199406060-00007.
3
Evaluation of the pharmacoeconomic literature.
Ann Surg. 2007 Jan;245(1):147-51. doi: 10.1097/01.sla.0000231802.83152.59.
4
Examining the quality of health economic analyses submitted to the Pharmaceutical Benefits Board in Sweden. The first year.
Eur J Health Econ. 2004 Dec;5(4):351-6. doi: 10.1007/s10198-004-0246-1.
Pharmacoeconomics. 1994 Oct;6(4):337-45. doi: 10.2165/00019053-199406040-00002.
4
Principles of pharmacoeconomic analysis of drug therapy.药物治疗的药物经济学分析原则。
Pharmacoeconomics. 1992 Jan;1(1):20-31. doi: 10.2165/00019053-199201010-00006.
5
Why a journal of pharmacoeconomics?为什么要有一本药物经济学杂志?
Pharmacoeconomics. 1992 Jan;1(1):2-4. doi: 10.2165/00019053-199201010-00002.
6
Evaluating the quality of published pharmacoeconomic evaluations.
Hosp Pharm. 1995 Feb;30(2):146-8, 151-2.
7
Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine.卫生与医学成本效益报告建议。卫生与医学成本效益小组。
JAMA. 1996;276(16):1339-41. doi: 10.1001/jama.276.16.1339.
8
Quality assessment of economic evaluations in selected pharmacy, medical, and health economics journals.部分药学、医学及卫生经济学杂志中经济评估的质量评估
Ann Pharmacother. 1995 Jul-Aug;29(7-8):681-9. doi: 10.1177/106002809502907-805.
9
Evaluation of pharmacoeconomic studies: utilization of a checklist.
Ann Pharmacother. 1993 Sep;27(9):1126-33. doi: 10.1177/106002809302700919.
10
Methods of cost-effectiveness analysis: areas of consensus and debate.
Clin Ther. 1995 Jan-Feb;17(1):109-25. doi: 10.1016/0149-2918(95)80012-3.